Headache Disorders: New Advances in Management and Treatment Strategies
Deadline for manuscript submissions: 31 July 2024 | Viewed by 3757
Interests: headache; pain; neuromuscular disorders; epilepsy; neurooncology
Interests: headache; migraine; pain
The recent market release of monoclonal antibodies (MAbs), specifically targeting the calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP MAbs), based on the results of clinical trials and real-life data, appeared as a promising preventative option in both episodic and chronic migraine patients with a much higher efficacy/tolerability ratio, compared to the already available oral and injectable prophylactic treatment of armamentarium. Four anti-CGRP MAbs are currently in use for the prevention of episodic and chronic migraines, including erenumab used to target the CGRP-receptor and fremanezumab, galcanezumab and eptinezumab used to target the CGRP ligand. In addition, anti-CGRP MAbs can be used wth some degree of success as preventives in other headache disorders, such as cluster and post-traumatic headaches. There are, however, unmet needs associated with the prophylactic management of these headache disorders, because of inadequate headache frequency reduction in about one third of migraine patients and an even higher percentage of treatment failure in cluster and post-traumatic headache patients. Significant unmet needs are also present in the symptomatic management of these headache disorders. To overcome these issues, new acute pharmacological options for headaches have been studied in the last few years, including gepants, a class of small molecules that target the CGRP receptor, and ditans, a class of non-triptan serotonin receptor antagonists. Gepants have been also explored in migraine prevention.
The scope of this Special Issue is to summarize our existing knowledge on the pros and cons of modern therapies for headache disorders, to examine open clinical and pathogenetic issues and to explore future perspectives for future research to pursue. As such, both research papers and reviews are welcome. Thank you for agreeing to contribute towards the successful release of this Special Issue for the Journal of Clinical Medicine. The Co-Editors and I are confident that it will become a reference point for all those who want to know why, when, and how to treat headache patients with monoclonal antibodies that target the CGRP, gepants or ditans.
Dr. Andreas A. Argyriou
Dr. Vikelis Michail
Dr. Emmanouil V. Dermitzakis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cluster headache
- post-traumatic headache
- acute treatment
- calcitonin gene-related peptide
- monoclonal antibodies